Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TSH BiopharmROCO:8432 88 EV-to-EBIT is 4.20 as of Sep. 08, 2026, which is 71% below its 10-year median of 14.50. GuruFocus rates ROCO:8432 with a GF Score™ of 88/100 and a GF Value™ of NT$71.57 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 681 Drug Manufacturers companies, TSH Biopharm ranks better than 91.78% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
TSH Biopharm's Enterprise Value for the quarter that ended in Jun. 2026 was NT$1,161 Mil.
TSH Biopharm's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$271 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSH Biopharm EV-to-EBIT Related Terms
TSH Biopharm EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for TSH Biopharm's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, TSH Biopharm's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TSH Biopharm EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TSH Biopharm's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where TSH Biopharm's EV-to-EBIT falls into.
TSH Biopharm's current Enterprise Value is NT$1,138 Mil.
TSH Biopharm's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$271 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSH Biopharm (ROCO:8432) has a EV-to-EBIT of 4.20 as of Sep. 08, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on TSH Biopharm and its competitors. This is 71% below median its historical median of 14.50. According to the industry distribution chart, TSH Biopharm ranks #56 out of 681 companies in the Drug Manufacturers industry, placing it in the top 8.2%.
Is TSH Biopharm's EV-to-EBIT too high?
TSH Biopharm's current EV-to-EBIT of 4.20 is 71% below median its 10-year median of 14.50. The Drug Manufacturers industry median EV-to-EBIT is 16.01. TSH Biopharm's value of 4.20 is 73.8% below this industry median. Based on the distribution chart, TSH Biopharm ranks #56 out of 681 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, TSH Biopharm has a GF Score™ of 88/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TSH Biopharm's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, TSH Biopharm ranks #56 out of 681 companies for EV-to-EBIT. This places TSH Biopharm in the top 8% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 16.01. TSH Biopharm's value of 4.20 is 73.8% below this benchmark. While the company's 10-year median is 14.50 vs. the industry median of 16.01, TSH Biopharm has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.01, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TSH Biopharm's current EV-to-EBIT of 4.20 is 73.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on TSH Biopharm and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TSH Biopharm's current EV-to-EBIT is 4.20, which is 71% below median its own 10-year median of 14.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TSH Biopharm stock overvalued right now?
Based on GuruFocus' analysis, TSH Biopharm (ROCO:8432) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$71.57, compared to a current price of NT$50.30 — trading 29.7% below its estimated fair value. The current EV-to-EBIT is 4.20, which is 71% below median its 10-year median of 14.50 and 73.8% below the Drug Manufacturers industry median of 16.01. TSH Biopharm's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For TSH Biopharm (ROCO:8432), the current EV-to-EBIT is 4.20 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TSH Biopharm (ROCO:8432) Overvalued in 2026?
Based on GuruFocus' analysis, TSH Biopharm stock appears to be undervalued.
The current stock price of NT$50.30 is trading 29.7% below its estimated GF Value™ of NT$71.57.
GuruFocus considers TSH Biopharm to be Significantly Undervalued.
Key valuation signals for ROCO:8432:
EV-to-EBIT: 4.20 (71% below median its 10-year median of 14.50)
GF Value™: NT$71.57 vs. price of NT$50.30 (29.7% below fair value)
Industry Position: 73.8% below the Drug Manufacturers median (#56 of 681)
No single metric tells the full story. See the ROCO:8432 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TSH Biopharm Corp Ltd is engaged in sale of a variety of pharmaceuticals, chemical drugs and engaged in biotechnology services. The company specializes in the development, manufacture, and marketing of branded drugs for chronic diseases. Key therapeutic areas include cardiovascular, central nervous system, gastroenterology, and severe chronic diseases, alongside precision medicine/genetic testing services .The Company's revenue is earned domestically. It earns majority of its revenue from the sale of Lozenges.
88GF Score
Get the complete analysis for ROCO:8432
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:8432 has been successfully added to your 
